Patents by Inventor Eric A. Kitas

Eric A. Kitas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FBPase inhibitors for diabetes
    Patent number: 7868030
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: January 11, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marcel Gubler, Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Rudolf E. Minder, Brigitte Schott, Hans P. Wessel
  • NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES
    Publication number: 20090143448
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 4, 2009
    Inventors: Paul Hebeisen, Eric A. Kitas, Rudolf E. Minder, Peter Mohr, Hans Peter Wessel
  • NEW PYRIDINES AS FBPASE INHIBITORS FOR TREATMENT OF DIABETES
    Publication number: 20090143439
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof wherein the residues have the significance given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: November 24, 2008
    Publication date: June 4, 2009
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Peter Mohr, Hans Peter Wessel
  • Sulfonamide derivatives
    Publication number: 20080085928
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein L, R1, R2, m and n have the meaning given in claim 1 and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: September 24, 2007
    Publication date: April 10, 2008
    Inventors: Wolfgang Haap, Paul Hebeisen, Eric Kitas, Philipp Kohler, Holger Kuehne, Armin Ruf
  • New FBPase inhibitors for diabetes
    Publication number: 20070281979
    Abstract: Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R3 have the significance given in the application and which can be used in the form of pharmaceutical compositions.
    Type: Application
    Filed: May 30, 2007
    Publication date: December 6, 2007
    Inventors: Marcel Gubler, Wolfgang Haap, Paul Hebeisen, Eric A. Kitas, Bernd Kuhn, Rudolf E. Minder, Brigitte Schott, Hans P. Wessel
  • Fluoro substituted 2-oxo-azepan derivatives
    Publication number: 20070037789
    Abstract: The invention relates to compounds of general formula wherein R1, R2, R3/R3?, R4/R4? and R5/R5? are as defined in the specification and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are ?-secretase inhibitors which can be useful in the treatment of Alzheimer's disease or common cancers including, but not limited to, cervical carcinomas and breast carcinomas and malignancies of the hematopoietic system.
    Type: Application
    Filed: August 8, 2006
    Publication date: February 15, 2007
    Inventors: Alexander Flohr, Guido Galley, Roland Jakob-Roetne, Eric Kitas, Wolfgang Wostl
  • Fluorescently labeled growth hormone secretagogue
    Publication number: 20060073522
    Abstract: The present invention relates to a fluorescently labeled growth hormone secretagogue which can be used for the identification of compounds capable of binding to growth hormone secretagogue receptors, in particular by high throughput screening.
    Type: Application
    Filed: December 12, 2005
    Publication date: April 6, 2006
    Inventors: Thilo Enderle, Martin Graf, Cornelia Hertel, Sannah Zoffmann, Eric Kitas
  • Sulfonamides
    Publication number: 20060014945
    Abstract: The invention relates to compounds of the general formula in which R1, R2, R3, R4, R2?, R3?, R4?, R5, and X is —CHR— are as defined in the specification. The invention also provides pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures of such compounds. The invention further provides methods for the treatment of Alzheimer's disease or common cancers.
    Type: Application
    Filed: July 12, 2005
    Publication date: January 19, 2006
    Inventors: Guido Galley, Eric Kitas, Roland Jakob-Roetne
  • Fluorescently labeled growth hormone secretagogue
    Publication number: 20050085421
    Abstract: The present invention relates to a fluorescently labeled growth hormone secretagogue which can be used for the identification of compounds capable of binding to growth hormone secretagogue receptors, in particular by high throughput screening.
    Type: Application
    Filed: October 14, 2004
    Publication date: April 21, 2005
    Inventors: Thilo Enderle, Martin Graf, Cornelia Hertel, Sannah Zoffmann, Eric Kitas
  • Carbamic acid alkyl ester derivatives
    Publication number: 20050075327
    Abstract: The present invention provides compounds of the general formula wherein R4 is one of the following groups and R1, R2, R3, R7, R8, and R9 are as defined in the specification and pharmaceutically acceptable salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds are useful for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 27, 2004
    Publication date: April 7, 2005
    Inventors: Alexander Flohr, Guido Galley, Roland Jakob-Roetne, Eric Kitas, Jens-Uwe Peters, Wolfgang Wostl
  • Malonamide derivatives
    Publication number: 20050054633
    Abstract: The invention relates to malonamide derivatives of formula wherein each of the variables are as defined herein and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures thereof. These compounds are ?-secretase inhibitors and may be used for the treatment of Alzheimer's disease.
    Type: Application
    Filed: September 2, 2004
    Publication date: March 10, 2005
    Inventors: Alexander Flohr, Guido Galley, Roland Jakob-Roetne, Eric Kitas, Jens-Uwe Peters, Wolfgang Wostl
  • PYRROLIDINE COMPOUNDS
    Publication number: 20020040048
    Abstract: The present invention relates to a pyrrolidine compound and pharmaceutically acceptable esters and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
    Type: Application
    Filed: July 6, 2001
    Publication date: April 4, 2002
    Inventors: Johannes Aebi, Henrietta Dehmlow, Eric A. Kitas